 Akari Therapeutics, Plc AKTX, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement C5 andor leukotriene LTB4 systems are implicated, today announced that Clive Richardson, Chief Executive Officer, will participate and host investor meetings during the STRH Life Sciences Virtual Meeting Series. Investors interested in arranging a virtual meeting with the Companys management during this conference should contact the conference coordinator. 